title: Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.
authors.affiliation: Medical College of Wisconsin, Department of Radiology, Milwaukee, Wisconsin.
authors.forename: Jerrold L
authors.initials: JL
authors.lastname: Boxerman
authors.affiliation: Medical College of Wisconsin, Department of Radiology, Milwaukee, Wisconsin.
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Schmainda
authors.affiliation: Medical College of Wisconsin, Department of Radiology, Milwaukee, Wisconsin.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Medical College of Wisconsin, Department of Radiology, Milwaukee, Wisconsin.
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Barboriak
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000098:blood supply*; D005260:Female; D005909:Glioblastoma / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab